These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32160610)

  • 21. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
    Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
    Naqvi K; Daver N; Pemmaraju N; Bose P; Garcia-Manero G; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Lymphoma; 2017 Apr; 58(4):866-871. PubMed ID: 27494751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
    Montesinos P; Roboz GJ; Bulabois CE; Subklewe M; Platzbecker U; Ofran Y; Papayannidis C; Wierzbowska A; Shin HJ; Doronin V; Deneberg S; Yeh SP; Ozcan MA; Knapper S; Cortes J; Pollyea DA; Ossenkoppele G; Giralt S; Döhner H; Heuser M; Xiu L; Singh I; Huang F; Larsen JS; Wei AH
    Leukemia; 2021 Jan; 35(1):62-74. PubMed ID: 32203138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 immunohistochemistry correlates with
    Ruzinova MB; Lee YS; Duncavage EJ; Welch JS
    Haematologica; 2019 Aug; 104(8):e345-e348. PubMed ID: 30792212
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of advanced phase myeloproliferative neoplasms.
    Marcellino B; Mascarenhas J
    Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
    Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H
    Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
    Systchenko T; Chomel JC; Gallego-Hernanz P; Moya N; Desmier D; Maillard N; Bobin A; Vonfeld M; Gardeney H; Cayssials E E; Torregrosa J
    Br J Haematol; 2023 Jul; 202(2):284-288. PubMed ID: 37183377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
    Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
    Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
    Chauvet P; Nibourel O; Berthon C; Goursaud L; Carpentier B; Lionne-Huyghe P; Wemeau M; Quesnel B
    Leuk Res; 2022 Jul; 118():106871. PubMed ID: 35633618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
    Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
    Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
    Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
    Bewersdorf JP; Rampal RK
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
    Kantarjian HM; Thomas XG; Dmoszynska A; Wierzbowska A; Mazur G; Mayer J; Gau JP; Chou WC; Buckstein R; Cermak J; Kuo CY; Oriol A; Ravandi F; Faderl S; Delaunay J; Lysák D; Minden M; Arthur C
    J Clin Oncol; 2012 Jul; 30(21):2670-7. PubMed ID: 22689805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
    Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
    Patel AA; Yoon JJ; Johnston H; Davidson MB; Shallis RM; Chen EC; Burkart M; Oh TS; Iyer SG; Madarang E; Muthiah C; Gross I; Dean R; Kassner J; Viswabandya A; Madero-Marroquin R; Rampal RK; Guru Murthy GS; Bradley T; Abaza Y; Garcia JS; Gupta V; Pettit KM; Cursio JF; Odenike O
    Blood Adv; 2024 Jul; 8(13):3468-3477. PubMed ID: 38739724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
    Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
    Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
    Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
    Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
    Benton CB; Tanaka M; Wilson C; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2015 Apr; 39(4):419-23. PubMed ID: 25687833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.